Through years of development, our team has built a comprehensive oncology
portfolio that covers the full cycle of cancer management, addressing needs and challenges from early
screening, diagnosis & monitoring, and biopharma development services. While continuously carrying out
scientific and technological innovation, we efficiently transform these breakthroughs into clinical
applications, which have served tens of thousands of patients, and dozens of scientific research institutions
and pharmaceutical enterprises across China. See our journey below.
Genetron Health signed a collaboration agreement with AstraZeneca R&D China for the joint
development in China of NGS-based tumor-informed (personalized) MRD tests for various solid tumor types.
Genetron Health’s liver cancer screening results and technology findings are included in the expert
consensus on the role of hematological markers in the early clinical screening of hepatocellular carcinoma
– submitted by the Infectious Disease Prevention and Control Division of the Chinese Preventive Medicine
Genetron Health’s multi-gene mutation detection kit Onco PanScan obtains CE Mark